A real world, retrospective study of Insulin Degludec/Aspart (IDegAsp) and Insulin Glargine U300 (IGlarU300) in patients with Type 2 Diabetes Mellitus
Latest Information Update: 25 May 2021
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CRIGDA
Most Recent Events
- 25 May 2021 New trial record
- 18 May 2021 Results published in the International Journal of Clinical Practice